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Psoriasis is a common infl  ammatory skin dis-
ease that aff  ects  2% of the population. The 
disease may present in several diff  erent forms, 
but the most common (>80% of cases) is 
chronic plaque psoriasis, consisting of red, 
heavily scaled, well-demarcated plaques on el-
bows, knees, scalp, and lower back, although 
any skin surface may be involved (1). Psoriasis 
may also aff  ect the nails in 50% of patients, and 
a seronegative arthritis, psoriatic arthritis, oc-
curs in  10%. Currently, there is no cure for 
psoriasis, and although rarely fatal, the disease 
causes considerable morbidity and impairment 
of quality of life (2). Early-onset psoriasis (that 
presenting before the age of 40) has a strong 
familial component. At least eight chromo-
somal susceptibility loci have been identifi  ed, 
the strongest linkage being to chromosome 6p 
and, in particular, to HLA-Cw6 (3). To date, 
no gene or gene product has been specifi  cally 
linked to psoriasis. Development of the skin 
lesions of psoriasis is contingent on environ-
mental triggers, including β-hemolytic strep-
tococcal pharyngitis, stress, and various drugs, 
such as β blockers and lithium, in genetically 
predisposed individuals.
On routine histology, plaques of psoriasis 
show abnormal proliferation and diff  erentia-
tion of epidermal keratinocytes. Current think-
ing is that psoriasis is mediated by T cells (4). 
An established plaque of psoriasis is character-
ized by an infi  ltration of activated CD45RO+ 
memory/eff  ector T cells, with CD8+ T cells 
predominating in the epidermis. The majority 
(85%) of T cells in plaques of psoriasis are cu-
taneous lymphocyte–associated antigen positive 
(5). It is thought that T cells become activated 
and acquire cutaneous lymphocyte–associated 
antigen expression at extracutaneous sites, such 
as the tonsil. One theory is that streptococcal 
M protein involved in induction of cutane-
ous lymphocyte–associated antigen expression 
on T cells may lead to cross-reaction with an 
as-yet-unknown epitope of epidermal keratin. 
Plaques of psoriasis are characterized by a pre-
dominance of Th1 cytokines, particularly IL-2
and IFN-γ, coupled with increased activity 
of TNF-α (6). A central role for T cells in the 
pathogenesis of psoriasis has been underscored 
further by the observation that T cell–targeted 
therapies such as ciclosporin (7), an IL-2 fusion 
toxin (8), and an anti-CD11a monoclonal an-
tibody (efalizumab; reference 9) are eff  ective 
therapies for this disease. Furthermore, the unin-
volved skin of patients with psoriasis transplanted 
onto the fl  anks of SCID mice can be converted 
to psoriasis by injection of activated autologous 
peripheral blood mononuclear cells (10).
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We have examined whether psoriasis is associated with systemic effects on epidermal 
Langerhans cell (LC) function and, specifi  cally, the migration of LCs from the skin. Com-
pared with normal skin, the frequency and morphology of epidermal LCs in uninvolved skin 
from patients with psoriasis was normal. However, mobilization of these cells in response to 
stimuli that normally induce migration (chemical allergen, tumor necrosis factor 𝗂 [TNF-𝗂], 
and interleukin-1𝗃 [IL-1𝗃]) was largely absent, despite the fact that treatment with 
TNF-𝗂 and IL-1𝗃 was associated with comparable infl  ammatory reactions in patients and 
controls. The failure of LC migration from uninvolved skin was not attributable to altered 
expression of receptors for IL-1𝗃 or TNF-𝗂 that are required for mobilization, nor was 
there an association with induced cutaneous cytokine expression. Although a role for 
altered dynamics of LC migration/turnover has not been formally excluded, these data 
reveal a very consistent decrement of LC function in psoriasis that may play a decisive role 
in disease pathogenesis.
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DCs are a unique population of leukocytes that regu-
late immune responses and have the ability to interact with 
and activate T cells (11). Langerhans cells (LCs) are members 
of this wider family of DCs. LCs reside in the epidermis, 
where they serve as sentinels of the immune system, their 
responsibilities being to sample the external environment for 
changes and challenges and to deliver information (antigen) 
to T cells within skin-draining lymph nodes. The ability of 
LCs to migrate from epidermis to regional lymph nodes is 
thus of pivotal importance to the induction of cutaneous 
immune responses. The initiation and regulation of LC mo-
bilization and migration are orchestrated by cutaneous cyto-
kines and chemokines. Collectively, the available data reveal 
that under normal circumstances the stimulation by chemical 
allergens of LC migration away from the epidermis is de-
pendent on the local availability of IL-1β and TNF-α. We 
have previously shown that exposure of human volunteers 
either to a contact allergen (diphenylcyclopropenone [DPC]) 
by topical administration (12) or to TNF-α (13) or IL-1β 
(14) by intradermal injection results in a substantial (20–30%) 
reduction in the frequency of epidermal LCs. This is due to 
the migration of epidermal LCs to draining lymph nodes. 
The observation that only a proportion of human LCs is able 
to mobilize in response to cytokine or allergen stimulus is 
believed to refl  ect the fact that functional heterogeneity ex-
ists amongst epidermal LCs.
The role of LCs in the pathogenesis of psoriasis is poorly 
understood. There are confl  icting reports that the frequency 
of epidermal LCs in the uninvolved skin of psoriasis patients 
is the same, increased, or decreased compared with the skin of 
normal volunteers (15, 16). Clinical research points to a func-
tional impairment in LC function in patients with psoriasis. 
This evidence consists of impaired contact hypersensitivity to 
experimental allergens such as 2,4-dinitrochlorobenzene (17) 
and the observation that allergic contact dermatitis is rela-
tively rare in patients with psoriasis (18). These observations 
led us to investigate LC function in psoriasis, particularly mi-
gration in response to the classic proinfl  ammatory cytokines 
IL-1β or TNF-α and to the contact allergen DPC.
RESULTS
LC migration
We have investigated the integrity of LC migration in the 
uninvolved skin of patients with psoriasis. In the fi  rst series of 
experiments, allergen-induced LC migration was examined. 
10 patients and one normal volunteer were exposed topically 
to the contact allergen DPC (2% in acetone) or to acetone 
alone, and punch biopsies were taken 17 h later for assess-
ment of CD1a+ LC numbers (Fig. 1 a). These results are 
shown in comparison with historical data, where LC den-
sities were measured as a function of both CD1a (10 subjects) 
and HLA-DR (fi  ve subjects) expression (Fig. 1 a, bottom; 
reference 12). Topical application of 2% DPC to uninvolved 
psoriatic skin failed to induce marked LC mobilization, with 
only one patient responding to DPC with a decrease in LC 
densities (22% reduction; Fig. 1 a, top). In contrast, normal 
healthy volunteers responded vigorously to chemical aller-
gen. The response to DPC in the healthy volunteer exam-
ined concurrently (32.5% reduction) was similar to historical 
control values (Fig. 1 a, bottom), resulting in a signifi  cant 
(P < 0.01) reduction of 27.5% in LC densities in the skin of 
normal healthy volunteers exposed to DPC.
To investigate whether the observed impairment of 
DPC-induced LC migration was due to a lack of produc-
tion of appropriate cytokines required for LC mobilization, 
homologous recombinant TNF-α or IL-1β were delivered 
intradermally into the skin of patients or normal volunteers. 
Treatment with 200 U TNF-α for 2 h (conditions shown 
previously to result in optimal LC migration in normal skin; 
reference 13) did not alter CD1a+ LC numbers in the un-
involved skin of psoriasis patients compared with exposure 
to saline alone (Fig. 1 b, top). As expected, in two healthy 
volunteers treated concurrently, exposure to 200 U TNF-α 
induced LC migration that was similar to historical control 
data, with an overall mean reduction in CD1a+ LC numbers 
of 24% (P < 0.01; Fig. 1 b, bottom). Failure to detect LC 
migration in uninvolved psoriatic skin was not the result of a 
more rapid migration (19), with intradermal administration of 
200 U TNF-α to either one normal volunteer or one patient 
failing to stimulate LC mobilization after 30 min of exposure 
(unpublished data). Furthermore, LCs in psoriatic skin failed 
to respond to a higher dose (500 U) of TNF-α. Thus, in a 
further seven patients, no TNF-α (500 U)–mediated reduc-
tion in LC frequency was recorded, regardless of whether 
Figure 1.  Impaired allergen- and cytokine-induced LC migration in 
the uninvolved skin of patients with psoriasis. Patients and normal 
healthy volunteers were treated topically with acetone (ac) or 2% DPC 
(a) or were injected intradermally with homologous recombinant TNF-α 
(b, 200 U; c, 500 U) or IL-1β (d, 50 U; e and f, 100 U), or saline (sal). Punch 
biopsies were taken from treated sites 17 h after treatment with DPC, 2 h 
after injection of TNF-α, and 2 h (e) or 4 h (f) after the administration of 
IL-1β. Epidermal sheets were prepared, and the density of CD1a+ LCs 
(solid line) or HLA-DR+ LCs (dotted line) was assessed after indirect 
 immunofl  uorescence staining. For each volunteer, results are displayed 
as the mean number of LC/mm2 for test (DPC or cytokine) versus control 
(ac or sal). Each line represents the response of a different individual. 
Solid circles represent data from current investigation, and open circles 
represent historical data (12–14).JEM VOL. 203, April 17, 2006  955
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LCs were detected on the basis of CD1a (three patients) ex-
pression or HLA-DR (four patients) staining (Fig. 1 c, top). 
In contrast, 500 U TNF-α caused a decrease in CD1a+ LC 
densities in two normal volunteers tested concurrently and 
in historical controls comprising 13 (CD1a, 9; HLA-DR, 4) 
normal individuals examined under identical exposure condi-
tions (Fig. 1 c, bottom). In total, the mean reduction in epi-
dermal LC densities provoked by 500 U TNF-α was 22.3% 
(P < 0.01) in normal skin. In subsequent experiments, we ex-
plored the hypothesis that impaired LC migration in psoriasis 
patients might be due to lack of biologically active IL-1β. To 
address this, four patients and one concurrent normal volun-
teer received 50 U IL-1β intradermally or saline alone, and 
biopsies were taken 2 h later, conditions established previ-
ously for vigorous LC migration in normal human skin (14). 
In this cohort of volunteers, treatment with 50 U IL-1β was 
associated with no change in CD1a+ LC densities in unin-
volved psoriatic skin (Fig. 1 d, top). However, this dose of 
IL-1β stimulated the expected reduction in CD1a+ LC num-
bers in the corresponding normal subject, and together with 
historical control data, a mean IL-1β–mediated reduction in 
CD1a+ LC frequencies in normal skin of 25.4% (P < 0.01) 
was observed (Fig. 1 d, bottom). To determine whether LCs 
in uninvolved psoriatic skin are less responsive to IL-1β, the 
activity of a higher dose (100 U) of IL-1β was examined (14). 
In six psoriasis patients injected with 100 U IL-1β, no change 
in either CD1a+ (n = 3) or HLA-DR+ (n = 3) LC numbers 
was evident 2 h after exposure (Fig. 1 e, top). However, LC 
mobilization was observed in one healthy volunteer exam-
ined concurrently and in four historical control subjects who 
participated in a previous study to give an overall reduction in 
CD1a+ LC numbers of 19.4% (P < 0.01; Fig. 1 e, bottom). 
Finally, we examined whether LCs in uninvolved psoriatic 
skin would respond to IL-1β with delayed kinetics compared 
with LCs in normal skin. Thus, a further three patients were 
exposed to 100 U IL-1β for 4 h. Again, LCs in the unin-
volved skin of psoriasis patients failed to migrate in response 
to treatment with 100 U IL-1β (Fig. 1 f, top), under condi-
tions where all normal individuals responded to this dose of 
IL-1β in a previous investigation with a mean reduction in 
LC numbers of 20.6% (P < 0.01; Fig. 1 f, bottom).
LC density and morphology
Baseline LC frequencies and morphology at resting (control) 
skin sites have been collated during these experiments. Rest-
ing LC values varied considerably between individuals but 
were not signifi  cantly diff  erent between psoriasis patients and 
control subjects. Thus, densities of CD1a+ LCs ranged from 
660 to 1,583 LC/mm2 in the uninvolved skin of psoriasis pa-
tients and from 562 to 1,493 LC/mm2 in normal volunteers, 
with similar values recorded for HLA-DR+ LCs (Fig. 2 a). 
Overall, the mean (± SD) epidermal CD1a+ and HLA-DR+ 
LC values for uninvolved psoriatic skin (1,101 ± 215 LC/mm2, 
n = 27, and 1,058 ± 222 LC/mm2, n = 7, respectively) and 
normal skin (1,100 ± 210 LC/mm2, n = 43, and 1,218 ± 168 
LC/mm2, n = 11, respectively) did not diff  er signifi  cantly. 
Examination of LC morphology at control-treated sites re-
vealed no marked diff  erences in the dendritic appearance of 
LCs in uninvolved psoriatic or normal skin samples, regard-
less of whether epidermal sheets were examined by fl  uores-
cence or confocal microscopy (Fig. 2, b and c, respectively). 
Similarly, there were no apparent diff  erences in the level of 
expression of CD1a or HLA-DR determinants between vol-
unteer groups. However, small focal points of cells stained 
more intensely for HLA-DR were observed occasionally in 
Figure 2.  Epidermal LCs in uninvolved psoriatic skin appear similar 
to LCs in normal skin. (a) Comparison of epidermal CD1a+ and HLA-
DR+ LC numbers at sites treated with control (acetone or saline) derived 
from data displayed in Fig. 1 for uninvolved psoriatic and normal skin. 
Solid line represents the mean LC value for each group. (b) Distribution of 
CD1a+ LCs in epidermal sheets prepared from uninvolved psoriatic skin 
and normal skin biopsies observed by fl  uorescence microscopy. (c) Confocal 
images of CD1a+ LCs in epidermal sheets prepared from uninvolved 
psoriatic skin and normal skin biopsies. (d and e) Histological examination 
of skin sections prepared from uninvolved psoriatic or normal skin 
  biopsies 2 h after exposure to saline (d) or TNF-α (e).956  IMPAIRED LC MIGRATION IN PSORIASIS | Cumberbatch et al.
epidermal sheets from the uninvolved skin of psoriasis pa-
tients, which were not apparent in normal skin (unpublished 
data) and may be due to low-level infl  ammation present 
even in the normal-appearing skin of patients with psoriasis. 
  Although the morphology of LCs varied somewhat between 
subjects from both groups, clear and consistent changes in 
LC morphology were not observed routinely in uninvolved 
psoriatic skin compared with normal skin, at either control 
or treated (DPC or cytokine) skin sites. As such, it was not 
possible to form reliable conclusions regarding the matura-
tion status of LCs under these conditions, which suggests that 
a more quantitative approach is required.
Clinical observations and histological assessment
We reported previously that topical exposure of normal skin 
to DPC results in an early infl  ammatory response visible after 
17 h in  50% of volunteers and a delayed, more aggres-
sive reaction (graded 2–3) sometimes requiring treatment in 
>50% of individuals after 10 d (12). We report here that, in 
contrast, DPC failed to induce an early infl  ammatory reaction 
in uninvolved psoriatic skin in any of the patients examined, 
and only two patients responded with a delayed infl  ammatory 
reaction (graded 1 and 2). There was no association between 
infl  ammation and LC migration in these patients. The single 
normal volunteer treated concurrently with DPC in this study 
failed to develop an early infl  ammatory response but acquired 
a severe reaction (grade 3) after 10 d, which required treat-
ment. Injection of TNF-α or IL-1β caused equivalent local 
erythematous reactions (graded 1–2) in a similar proportion of 
subjects in both volunteer groups. The presence of an infl  am-
matory response to cytokine in uninvolved psoriatic skin was 
confi  rmed histologically in four patients treated with 500 U 
TNF-α (histological score 0–2) and fi  ve patients exposed to 
50 U IL-1β (scored 1–3), the nature of the infl  ammatory 
cell infi  ltrate being consistent with that reported previously 
for normal skin (Fig. 2, d and e; reference 13). Injection of 
cytokine was tolerated equally in both groups of volunteers 
with minimal systemic side eff  ects. Pulse rate, blood pressure, 
and body temperature did not change signifi  cantly over the 
2–4-h period of examination.
Basal and inducible cutaneous cytokine production
To determine whether impaired cytokine-induced LC mi-
gration in uninvolved psoriatic skin is due to a failure of LCs 
to receive both cytokine signals for migration, we measured 
the level of TNF-α and IL-1β in blister fl  uids prepared from 
uninvolved psoriatic and normal skin sites after injection of 
each of these cytokines. In addition, we looked at other pro-
infl  ammatory and antiinfl  ammatory cytokines involved in 
cutaneous immune responses (IL-6, IL-8, IL-10, IL-12p70, 
GM-CSF, and IFN-γ). In each case, individuals received in-
jections of cytokine (IL-1β or TNF-α) or saline alone as 
control, enabling comparisons of both basal and inducible 
cytokine production to be made (Fig. 3). We found that 
administration of 100 U IL-1β up-regulated TNF-α secre-
tion in all volunteers examined; however, the response was 
signifi  cantly greater in psoriasis patients (3.7-fold increase; 
P < 0.01; n = 5) than in normal subjects (2.2-fold increase; 
n = 4; Fig. 3 a, top). Conversely, TNF-α also promoted 
increased IL-1β secretion in all cases, although the response 
in psoriasis patients (3.5-fold increase; n = 5) was not sig-
nifi  cantly diff  erent from that observed in normal controls 
(2.8-fold increase; n = 2; Fig. 3 a, bottom). Furthermore, 
mean (± SE) basal IL-1β and TNF-α levels at saline-treated 
sites in uninvolved psoriatic skin (IL-1β, 4.3 ± 2.0 pg/mg; 
TNF-α, 6.9 ± 1.2 pg/mg; n = 10) were equivalent to those 
found in normal skin (IL-1β, 3.0 ± 0.9 pg/mg; TNF-α, 6.2 ± 
2.4 pg/mg; n = 6). A similar pattern emerged for all other 
cytokines examined (Fig. 3 b). Thus, basal cytokine levels 
in saline-treated uninvolved psoriatic skin were comparable 
with those found at control sites in normal skin. In addi-
tion, although some variability existed between volunteers 
in basal cytokine levels and the extent of enhanced cytokine 
production, administration of either TNF-α or IL-1β gener-
ally enhanced production of all cytokines examined for both 
psoriasis patients and normal volunteers. However, no sig-
nifi  cant diff  erences were apparent for psoriasis patients ver-
sus normal subjects. To investigate the possibility that raised 
IL-1R antagonist (IL-1Ra) levels in patients with psoriasis 
negate IL-1 responses, suction blister fl  uids were further ana-
lyzed by ELISA for the presence of this antagonist. However, 
similar levels of IL-1Ra were found to be present in blister 
fl  uids taken from resting (saline treated) skin sites (normal, 
1.92 ± 0.3 ng/mg, mean ± SE of n = 6; psoriasis, 1.86 ± 
0.4 ng/mg, mean ± SE of n = 10) for both volunteer groups, 
and this did not alter with cytokine (TNF-α or IL-1β) injec-
tion (unpublished data).
Figure 3.  Comparable basal and inducible cutaneous cytokine 
  secretion in blister fl  uids raised at uninvolved psoriatic and normal 
skin sites. Psoriasis patients and normal volunteers were exposed intra-
dermally to 100 U IL-1β or 500 U TNF-α. Suction blister equipment was 
applied and blister fl  uid aspirated after 90–120 min for cytokine array 
analysis by Luminex. (a) Individual responses for IL-1β–induced TNF-α 
production (top) and TNF-α–induced IL-1β secretion (bottom) are dis-
played. (b) Mean (± SE) cytokine levels for IL-6, IL-8, IL-10, IL-12p70, 
GM-CSF, and IFN-γ observed after injection of saline (sal) alone, IL-1β, or 
TNF-α. Mean (± range) is displayed for TNF-α–induced cytokine secretion 
in normal skin. Cytokine levels are displayed as picogram/milligram of 
protein measured in blister fl  uid samples using a modifi  ed Lowry.JEM VOL. 203, April 17, 2006  957
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Expression by LCs of IL-1RI and TNF-R2
We next examined whether the failure to induce mobiliza-
tion of LCs in uninvolved psoriatic skin might be explained 
at the level of IL-1RI or TNF-R2 expression, both of which 
are expressed by LCs in normal human skin (20). For each 
analysis, epidermal cell suspensions were prepared concur-
rently from punch biopsies taken from one normal individual 
and from the uninvolved skin of one patient with psoriasis. 
Cells were dually stained for either IL-1RI or TNF-R2, to-
gether with CD1a to identify LCs, before analysis by two-
color fl  ow cytometry. In total, seven matched comparisons 
were conducted for IL-1RI, three of which included con-
current measurements for TNF-R2 (Fig. 4). We found that 
the frequency of CD1a+ LCs (1–2%) in epidermal cell sus-
pensions did not diff  er between volunteer groups, which is 
consistent with the data presented in Fig. 1. However, al-
though the percentage of CD1a+ LCs expressing IL-1RI or 
TNF-R2 varied between individuals, no overall diff  erence in 
either the proportion of LCs expressing these cytokine recep-
tors or their level of expression on LCs was observed. Thus, 
the percentage of CD1a+ LCs expressing IL-1RI ranged 
from 40 to 74% (mean ± SE, 63.3 ± 4.5%) for normal vol-
unteers and from 48 to 78% (61.7 ± 4.3%) for psoriasis pa-
tients. Comparisons of TNF-R2 expression by LCs revealed 
that 18.4 ± 5.7% (range, 9–25%) and 18.6 ± 4.4% (range, 
12–23%) of CD1a+ LCs in normal and uninvolved psoriatic 
skin displayed this cytokine receptor, respectively. These re-
sults demonstrate that IL-1RI and TNF-R2 are present on 
LCs in the uninvolved skin of patients with psoriasis and to 
the same extent as observed in normal skin.
D  I  S  C  U  S  S  I  O  N 
Collectively, these results clearly demonstrate that LC func-
tion is abnormal in uninvolved skin from patients with pso-
riasis. This is particularly remarkable given the observations 
that within nonlesional skin the numbers and morphological 
characteristics of epidermal LCs were found to be entirely 
normal. It could be argued that the signifi  cant impairment 
of LC function in psoriasis is a consequence of cutaneous 
infl  ammation. The observation that LC migration was either 
absent or impaired irrespective of the extent/severity of pso-
riasis is evidence that this is not the case.
It is now well established that the mobilization of epi-
dermal LCs is dependent on both IL-1β and TNF-α (11, 
13) and that if, in experimental systems, either one of these 
cytokines is unavailable, then migration is no longer induc-
ible (21, 22). In humans also there is evidence that a decre-
ment in IL-1β associated with aging (23) or an inhibition 
of cutaneous TNF-α production resulting from local treat-
ment with lactoferrin (13, 14) is in each case characterized by 
impaired LC migration. In the current investigations, how-
ever, it is apparent, that the absence of LC mobilization is not 
attributable to a lack of cytokine signals because migration 
could not be provoked by the local administration of either 
IL-1β or TNF-α under conditions where these cytokines 
were shown to cross-induce each other and where they are 
known to provoke migration of LCs from the epidermis of 
healthy volunteers. In addition, there is no reason to doubt 
that these cytokines were able to deliver signals to resident 
LCs in uninvolved skin. Thus, expression by LCs of the rel-
evant receptors, IL-1RI and TNF-R2 (11), were apparently 
normal, and in any event both cytokines were able to elicit 
infl  ammatory reactions in nonlesional psoriatic skin that were 
comparable with those observed in the skin of normal donors. 
Furthermore, patterns of cytokine production induced by 
local exposure to either IL-1β or TNF-α and measured in 
blister fl  uid in normal skin from healthy donors did not diff  er 
from those observed in nonlesional skin.
These observations pose questions regarding the cellu-
lar and molecular bases for impaired or absent LC migration 
in apparently unaff  ected skin from patients with psoriasis. 
Myriad changes have been identifi  ed in psoriatic lesions com-
pared with the healthy skin of normal subjects. Among these 
are disease-related changes that might infl  uence responses of 
LCs to cytokines and other stimuli, such as overexpression 
of IL-1Ra (24), the expression of factors such as macrophage 
infl  ammatory protein 3α (CCL20; references 25, 26), which 
could serve to encourage retention of LCs within infl  amed 
skin or other bioactive proteins that have been found to 
be overexpressed in psoriatic skin (IL-12, IL-20, interferon 
regulatory factor-2, transforming growth factor-α, and vari-
ous chemokines; references 27–31) and which might alone 
or in concert inhibit migration through as-yet-unidentifi  ed 
mechanisms. Although changes such as these, associated with 
disease progression, might be implicated as causes of the ab-
normal characteristics of LCs within plaques of psoriasis, it is 
harder to envisage how such mechanisms exert what would 
appear to be a systemic eff  ect of some magnitude on epider-
mal LCs, including cells resident within nonlesional skin. For 
example, there was no evidence in such skin of increased 
levels of IL-1Ra compared with healthy controls.
Figure 4.  Detectable IL-1RI and TNF-R2 expression on LCs in epi-
dermal cell suspensions prepared from normal healthy and unin-
volved psoriatic skin. Epidermal cell suspensions were dually stained for 
IL-1RI/CD1a (a) or TNF-R2/CD1a (b), or appropriate isotype control combi-
nations, and 105 cells were analyzed using a FACSCalibur fl  ow cytometer. 
Representative results for epidermal cell suspensions stained concurrently 
for IL-1RI and for TNF-R2, from one normal volunteer and one patient 
with psoriasis, are displayed.958  IMPAIRED LC MIGRATION IN PSORIASIS | Cumberbatch et al.
However, one possibility may reside in recent fi  ndings 
regarding the activity of plasmacytoid DCs (PDCs) that are 
found in increased numbers both in plaques of psoriasis and 
nearby uninvolved skin (32). The available evidence iden-
tifi  es IFN-α derived from activated PDCs as an important 
initiator of psoriasis (32). In this context it may be relevant 
that type 1 interferon (IFN-α/β) has been shown in vitro 
to inhibit the maturation of LCs and their migration in re-
sponse to the CCR7 ligand CCL21 (33). These data raise the 
possibility that expression of IFN-α/β by activated PDCs in 
involved and uninvolved skin in psoriasis may be associated 
with a generalized inhibition of LC migration.
However, it should not necessarily be inferred that unin-
volved skin in patients with psoriasis is comparable in every 
way with the normal skin of healthy subjects, and indeed it has 
been proposed that there exist diff  erences (of as-yet-uncertain 
importance or consistency) that can be identifi  ed by global 
gene expression analyses (34). Nevertheless, such a dramatic 
functional diff  erence as that described here has not previously 
been identifi  ed within nonlesional skin, and the expectation 
has been that the skin of susceptible subjects would, if any-
thing, be associated with enhanced traffi   c of LCs and other 
leukocytes (35). In support of the data described herein, im-
paired DC mobilization was also observed in a mouse model 
of atherosclerosis where infl  ammation of the skin was evident 
(36). Thus, impaired DC migration may represent an inher-
ent feature of other diseases with infl  ammatory pathologies. 
The interpretation in the context of psoriasis would be that 
LCs retained within the epidermis could present antigen lo-
cally to sustain or exacerbate a cutaneous infl  ammatory reac-
tion. Another concept with intriguing implications for the 
pathogenesis of psoriasis is the observation that LCs may play 
a regulatory role in cutaneous immunity (37). Thus, it was re-
ported that the aff  erent phase of contact hypersensitivity was 
enhanced in Langerin-diptheria toxin subunit A–transgenic 
mice, which constitutively lack epidermal LCs, raising the 
possibility that LCs not only serve to initiate adaptive immune 
responses but may also play a suppressive role. Furthermore, it 
was shown in these studies that the enhanced contact hyper-
sensitivity response most likely occurred through increased 
priming of T cells (37). This implies that a critical determi-
nant in psoriasis (a T cell–mediated disease) could arise from a 
lack of regulation from LCs early in the psoriatic process.
Another important consideration is that of dynamics of 
LC traffi   cking. Little is known about the turnover of LCs in 
human skin either under homeostatic or pathological condi-
tions. As such, it is not possible at this stage to exclude the 
possibility that altered kinetics of LC turnover in nonlesional 
psoriatic skin contribute to the apparent lack of LC migration 
observed here in response to infl  ammatory stimuli. Although 
we have highlighted a functional defect in LCs in nonlesional 
psoriatic skin that may have important implications for the 
disease process, it is important to note that the majority of 
cutaneous immune responses proceed normally in these pa-
tients, suggesting that other DC populations, such as dermal 
DCs, are unlikely to be similarly aff  ected.
The hypotheses we advance here are either that suscepti-
bility to the development of psoriasis is associated with (and 
possibly predicated on) abnormal epidermal biology that is 
manifested by impaired LC mobilization or, alternatively, 
that disease progression is characterized by systemic changes 
that aff  ect LC function. Irrespective of whether a systemic 
impairment of LC mobilization is related to disease predispo-
sition or disease progression, the factors that might result in 
altered function, or the absence of which may compromise 
function, have not yet been identifi  ed. However, one poten-
tial candidate worthy of consideration is interferon consensus 
sequence binding protein (38).
In conclusion, we have demonstrated that psoriasis is 
  associated with a considerable impairment of epidermal LC 
mobilization. These data provide clear evidence that, with 
respect to either cause or eff  ect, psoriasis is characterized by 
very substantial changes in LC biology.
MATERIALS AND METHODS
Patients. 47 patients with a dermatologist-confi  rmed diagnosis of chronic 
plaque psoriasis (25 female and 22 male; age range, 18–58 yr; mean age, 
40.9 yr) and 19 normal healthy volunteers (13 female and 6 male; age range, 
20–55 yr; mean age, 38.1 yr) were recruited for study. Three of the pso-
riasis patients and one of the normal individuals volunteered for two dif-
ferent aspects of the study. An additional 40 normal volunteers involved in 
previous studies (24 female and 20 male; age range, 19–56 yr; mean age, 
35.7 yr) were included for comparative purposes. Of these, one individual 
had volunteered for two diff  erent studies and three individuals also vol-
unteered for the current investigation. Patients had been off   systemic or 
photo therapy for psoriasis for at least 4 wk and were not using any active 
topical therapy, other than emollients, to the buttock or hip region at the 
time of the study. Clinical severity of psoriasis ranged from 1 to >70% body 
surface area involvement.
The study was approved by the Salford and Traff  ord Local Research 
Ethics Committee, and all subjects gave written, informed consent.
Exposure to allergen or cytokines. The skin-sensitizing chemical DPC 
(Calderdale and Huddersfi  eld National Health Service Trust) was dissolved 
in acetone. Subjects were exposed topically at sites (each 2 cm2 area) iden-
tifi  ed on the non–sun-exposed buttock to 50 μl of 2% (wt/vol) DPC in 
acetone or acetone alone. In some volunteers, DPC caused a delayed infl  am-
matory reaction that required treatment (clobetasol propionate, 0.5% cream 
or Dermovate [Glaxo Wellcome]). Homologous recombinant human TNF-α 
(specifi  c activity 3.6 × 107 U/mg by L929 assay; a gift from R.W. Groves, 
St Thomas’ Hospital, London, UK) and IL-1β (specifi  c activity >1 × 107 
U/mg; Insight Biotechnology Ltd.) were diluted in sterile normal saline to 
the appropriate concentrations. Subjects received 50-μl intradermal injec-
tions of cytokine diluted in saline or of sterile saline alone to sites identifi  ed 
on the non–sun-exposed buttock. For psoriasis patients, all treatments were 
delivered to sites on uninvolved skin of normal appearance >5 cm away 
from a plaque of psoriasis.
Biopsy. 6-mm punch biopsies were taken under local anesthesia (1% 
  lidocaine) from each of the treated sites after various periods of exposure. 
Biopsies were processed immediately for either analysis of epidermal LC 
frequency or histological examination.
Preparation and analysis of epidermal sheets. Biopsies were processed 
for analysis of epidermal CD1a+ or HLA-DR+ LCs as described previ-
ously (12). Samples were examined by fl  uorescence microscopy, and the 
frequency of stained cells was assessed in a blinded fashion using an eyepiece 
with a calibrated grid (0.32 × 0.213 mm at 40× magnifi  cation). For each 
sample, 50 consecutive fi  elds in the central portion of the biopsy were examined JEM VOL. 203, April 17, 2006  959
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and the results expressed as the mean number of cells/square millimeter. No 
specifi  c staining was observed in control experiments using mouse mono-
clonal IgG2a (clone DAK-G05; DakoCytomation) in place of the primary 
antibody. Images were acquired digitally using either a laser-scanning confo-
cal microscope (BX51; Olympus) system (Radiance 2100; Bio-Rad Labora-
tories) or a fl  uorescence microscope (BX50; Olympus) coupled with a color 
charge-coupled device camera (RS CoolSNAP; Photometrics) and Meta-
Morph Imaging System (version 4.01; Princeton Instruments).
Clinical assessment. All treated sites were assessed hourly for signs of ery-
thema (graded on a scale of 0 [none] to 3 [severe]) and induration (graded 
on a scale of 0 [none] to 3 [severe]), in addition to a subjective assessment 
of pain. Immediately before treatment and at half-hour intervals thereafter, 
blood pressure, pulse, and temperature were recorded.
Histological examination. Biopsies for histological examination were 
placed immediately in 4% buff  ered formal saline for routine processing to 
paraffi   n sections and staining with hematoxylin and eosin. Sections were 
examined in a blinded fashion. The extent of infl  ammation was scored using 
the following 5-point scale: 0, normal, no neutrophils present; 1, diapedesis 
only and neutrophils mostly intravascular; 2, mild vasculitis and neutrophils 
both intravascular and extravascular with mild vessel wall damage, including 
endothelial swelling; 3, marked vasculitis and neutrophils in walls of small 
vessels and arterioles with marked extravasation; and 4, epidermal spongiosis, 
a neutrophilic infi  ltrate in the papillary dermis, and a lymphocytic perivascular 
infi  ltrate in the middermis.
Suction blister formation. Suction blister cups (12 mm; Ventipress Oy) 
were applied to treated sites and a vacuum of 250 mmHg applied (39, 40). 
After suction blister formation (90–120 min), the pressure was released and 
blister fl  uid aspirated using a 23-gauge needle. Fluids were centrifuged for 
5 min in a microcentrifuge (MSE Micro Centaur; Fisher Scientifi  c) and 
frozen immediately at −70°C.
Cytokine array analysis and protein determination. Concentrations 
of TNF-α, IL-1β, IL-6, IL-8, IL-10, IL-12p40, GM-CSF, and IFN-γ were 
measured in blister fl  uids using the Bio-Plex cytokine and chemokine array 
system according to the manufacturer’s instructions (Bio-Rad Laboratories). 
Cytokine content was measured using a multiple analyte profi  ler (Luminex 
100; MiraiBio Hitachi Genetic Systems). Protein content was determined 
using a modifi  cation of the Lowry assay (41), the Bio-Rad DC protein assay 
(Bio-Rad Laboratories), a colorimetric assay for determination of protein 
concentration. The cytokine content of blister fl  uid samples is expressed as 
picograms of cytokine/milligrams of protein.
Measurement of IL-1Ra. The IL-1Ra content of suction blister fl  uids 
was measured by ELISA (IL-1Ra Cytoscreen kit; Biosource International) 
according to the manufacturer’s instructions, and results were expressed as 
nanogram of cytokine/milligram of protein.
Flow cytometric analysis of epidermal cell suspensions. Two 6-mm 
punch biopsies were taken from untreated non–sun-exposed buttock skin. 
In the case of psoriasis patients, biopsies were taken from normal-appearing 
untreated non–sun-exposed buttock skin >5 cm from a plaque of psoriasis. 
Biopsies were trimmed of underlying fat using a scalpel, washed thoroughly 
in PBS, and incubated for 60 min at 37°C with 0.4% trypsin and 0.2% EDTA 
(Invitrogen). Samples were washed thoroughly in RPMI-1640 growth me-
dium (Invitrogen) supplemented with 25 mM Hepes, 500 μg/ml streptomy-
cin and 500 U/ml penicillin (RPMI) containing 20% heat-inactivated FCS. 
Epidermal cells were separated from the underlying dermis by gentle scrap-
ing with a scalpel and a single cell suspension prepared by gentle mechanical 
disaggregation through 200-mesh stainless steel gauze. Cells were washed 
twice in RPMI containing 20% FCS and resuspended in RPMI containing 
10% FCS (RPMI-FCS). For analysis of IL-1RI and TNF-R2 expression by 
LCs, epidermal cell suspensions were incubated fi  rst with rat anti–human 
IL-1RI (CD121a, clone RMHL1-1, rat IgG2a; Serotec, Oxford, UK), rat 
anti–human TNF-R2 (CD120b, clone hTNFR-M1, rat IgG2b; BD Bio-
sciences), or isotype-matched control antibodies (rat IgG2a [clone R35-95] 
or rat IgG2b [clone R35-38]; BD Biosciences), each diluted to 10 μg/ml, 
followed by R-phycoerythrin-conjugated F(ab’)2 goat anti–rat IgG diluted 
1:50. Subsequently, cells were blocked with mouse serum (1:10), followed 
by treatment with FITC-conjugated mouse anti–human CD1a (clone 
HI149, mouse IgG1; BD Biosciences) diluted 1:50. Cell staining was ana-
lyzed by two-color fl  ow cytometry of 105 cells using a FACSCalibur fl  ow 
cytometer (BD Biosciences).
Statistical analyses. Diff  erences between LC values were considered by 
analysis of variance allowing for volunteer as a random eff  ect and treatment 
as a fi  xed eff  ect. Selected comparisons between treatment groups were com-
pared using a two-sided Student’s t test, based on the error mean square in 
the analysis of variance. TNF-α– and IL-1β–induced cytokine responses 
were considered by analysis of covariance.
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